Explore
For Enterprise
Join for Free
Log In

Arts et humanités
Business
Informatique
Science des données
Technologies de l'information
santé
Mathématiques et logique
Développement personnel
Sciences physiques et ingénierie
Sciences sociales
Apprentissage des langues
Diplômes et Certificats

Explorez l'intégralité de Coursera

Parcourir
Rechercher
For Enterprise
Connexion
Inscrivez-vous gratuitement

5 Medication Management (1:02:57)

Loading...

Prévenir les douleurs chroniques : l'approche des systèmes humains

Université du Minnesota

4.7 (116 notes) | 11K étudiants inscrits

Visualiser le programme de cours

Chronic pain is at epidemic levels and has become the highest-cost condition in health care. This course uses evidence-based science with creative and experiential learning to better understand chronic pain conditions and how they can be prevented through self-management in our cognitive, behavioral, physical, emotional, spiritual, social, and environmental realms. The goal of this course is to blend creative, experiential, and evidence-based teaching strategies to help participants understand chronic pain conditions and how a human systems approach can be applied to self-management strategies to reduce risk factors, enhance protective factors, and prevent chronic pain. There are four major objectives to the course; 1. Describe the prevalence, personal impact, and health care dilemma associated with chronic pain. 2. Recognize the clinical characteristics and underlying etiology of several common pain conditions and the peripheral, central, and genetic mechanisms of chronic pain 3. Based on the literature associated with risk and protective factors in the seven realms of our lives, learn specific strategies in each realm that can be employed daily to prevent chronic pain and enhance wellness. 4. Appreciate the value of a human systems approach to health care and how it can provide a basis for integrative, interdisciplinary, and individualized care to preventing pain and enhancing wellness. CONTINUING EDUCATION CREDIT Health Care Professionals Health care professionals who participate in this CE activity may submit this certificate statement of participation to their appropriate accrediting organizations or state boards for consideration of credit. The participant is responsible for determining whether this activity meets the requirements for acceptable continuing education. Email your Coursera certificate statement of completion to your appropriate organization.

Compétences que vous apprendrez

Chronic Pain Management, Plan, Pain Management, Opiod Addiction And Abuse Treatment

Avis

4.7 (116 notes)

5 stars
94 ratings
4 stars
15 ratings
3 stars
6 ratings
1 star
1 ratings

CS

Oct 11, 2017

Very informative! Lots of food for thought as a patient....need to redo the lessons again to fully digest it all. Well worth your time!

NJ

Jun 26, 2018

I found this course very effective in helping me manage my persistent pain. The advice and self-help techniques were very illuminating.

À partir de la leçon

Common Pain Conditions and their Mechanisms (Week 4)

1 Presentation 25:30

2 Diagnosis 35:03

3 Severity 23:15

4 Misconceptions 24:29

5 Medication Management (1:02:57)62:57

6 Lifestyle Management29:48

Last Scroll: The Rule of Gatherings3:21

Enseigné par

Dr. James Fricton, DDS, MS
Professor and Pain Specialist

>> Hello.

I'm Dr. Russell, I'm speaking to you from a recording studio

at the University of Minnesota in Minneapolis.

We're going to today finish the series on fibromyalgia.

With chapter three.

And there's going to be part A and part B.

This first slide shows a painting that I did several years ago,

after looking at a painting that was a little bit like it by a nother artist.

And my intention was to make a painting that was very relaxing.

But, the colors are too bright and too sharp and

too contrasting, and so I now have it as a wake-up slide.

We're talking on the second development or

second running of the MOOC Chronic Pain series and

so this is going to be the last of the.

The last chapter in the big picture of fibromyalgia,

so that you can see the first time that we met,

we talked about what is it, what is fibromyalgia?

And in that section, in that chapter, we talked about presentation of

the patients to a physician, or what symptoms they have,

what their diagnosis is, and how a physician would make that diagnosis.

Next, how the severity of the disorder would be measured,

and finally, what misconceptions have developed about fibromyalgia,

because there are a lot of them, and they clearly are misconceptions.

And so then in chapter two, we talked about,

what is wrong with people who have it?

Doctors would say that this is the pathogenesis of fibromyalgia, or

the pathology, or the chemical pathology of fibromyalgia.

And we included in that three sections, one on genetics,

one on the physiology of sleep, and pain, and mood, and their relationship to each

other, and finally the abnormal chemistry or biochemistry.

As it occurs in Fibromyalgia Syndrome.

So, now we're ready for chapter three and we'll do that in two segments.

The first one will be phar, pharmacologic therapy meaning medications,

used to help people with fibromyalgia to control their symptoms.

And the second will be non pharmacologic, or

lifestyle changes that can be utilized in the treatment of Fibromyalgia.

So, we started out by defining the state of the art for Fibromyalgia.

And we said that fibromyalgia is a common, chronically-painful,

soft tissue pain condition, which is characterized by persistent,

widespread pain, tenderness to pressure, and multisystem comorbidities.

Those comorbidities we defined, and they are important to the disorder,

because it is not just a pain disorder, it is a syndrome involving

a variety of constellation of symptoms, and manifestations.

Next, we say that relevant abnormalities,

which are objective in nature, that is they can be measured,

are detected by experiments in genetics, brain imaging, polysonography,

meaning the measurement of sleep or the observation of physiology of sleep.

Brain wave patterns, physiology, and chemistry.

And so, finally, this chapter brings us to a comment or

a statement about treatment, and that is, successful therapy is increasingly

based on correcting documented abnormalities.

Medication therapy should be combined with lifestyle changes, for optimal effects.

So, we begin with an acronym which can be used to help,

health care providers design a treatment program for Fibromyalgia.

It is referred to as ADEPT Living.

It begins with A of Attitude, and

implies that the physician and the patient, and

the patient's family, and others, we even think here of.

Politicians and emergency care workers and so

forth should know what Fibromyalgia is,

at least have some knowledge about it, and should not have an attitude

that is discriminating against people who have Fibromyalgia.

We then move to D, for Diagnosis.

And we think it's very important that the correct diagnosis be made, and

that the differential diagnosis, which means other conditions that

the person might have or might be somewhat similar be recognized.

We go then to E, standing for Education.

And we realize that it's quite important to tell people about Fibromyalgia, so

if they are experiencing Fibromyalgia as a clinical disorder,

and many of the manifestations of that disorder.

That can be very threat, threatening to them, and we want them to

be more comfortable with themselves and with the things they're dealing with.

So, that education is an important contributor to that confidence

in themselves and their future.

It also can be done, or it can be provided by counselors,

or by special evaluations and

education programs such as cognitive behavioral therapy.

Abbreviated here on the slide SCBT.

Cognitive behavioral therapy is a little bit like it sounds, but

it's not as easy as one could imagine it might be.

And that is, it is a design to help a person

who has a clinical disorder understand that disorder, and find ways of coping and

dealing with that disorder so it is not such a big distraction or

detractor from their lifestyle.

The next category is physical modalities and in that we include pacing,

exercise and treatments like hot water, physical therapy.

So, this can be done at home and there are things that can benefit from the skill and

expertise of a physical therapist or an occupational therapist.

Not to be ignored, I think, is the concept of pacing.

Pacing means that the person who is very limited by their symptoms.

Could decide to start everyday with a period of time,

lets say a half-hour of working on something.

Lets say that this is a homekeeper and that the person is

suffering from pain whenever standing for only, for long period of time.

And, but is necessary for

this person to take care of the dishes after a family has breakfast.

And it's dif, necessary to the do the laundry and

other chores that are important to the home existence.

And so we would suggest that they set a clock, maybe on the,

oven, or on an alarm clock in the area where they work,

and set that for maybe a half hour, and work during that half hour.

And then when it rings, sit down, rest, breathe comfortably.

Or read, or do something that completely relaxes the individual for

a half hour until the alarm sounds and then go back to the activity again.

And doing activity during the day in a pace manner,

alternating manner such as that can allow a person to still have energy and

ability to function at the end of the day.

And then, there is the section referred to as T, or Treatments.

Treatments would be recognized as

the purview of a therapist of some sort or a physician.

And in this case we have listed medications and, or

medical treatment and surgical treatment.

I think there is very little call for surgery in specific for fibromyalgia,

but there are occasions in which a fibromyalgia patient may dele, develop

the signs and symptoms of a disorder which should be treated surgically.

And, in that case, it seems that people with fibromyalgia heal normally after

surgery, and function fairly well, although they experience more pain

in association with the surgical procedure, or with the healing afterwards.

Medications we're going to focus on quite a bit, and

when one uses a therapy or a therapeutic model

than it's important we feel to evaluate how effective that model is.

So, we would then say, living is describing that evaluation that occurs

at periodic intervals, this is kind of interesting because most of

the things that we want to know about the fibromyalgia patient in

terms of their symptoms and signs can be assessed with a questionnaire.

And quest, validated questionnaire instruments have been developed for

this purpose.

It is very common now for a physician to place the information

from a clinical visit into a electronic medical record.

And those electronic medical records,

almost all have a section that is set aside for vital signs.

The vital signs one might be thinking about would be blood pressure, and

temperature, and height, and weight, and so forth.

But another way of thinking of vital signs is for example, pain and

pain measurement has become almost like a vital sign in the hospital

evaluated almost everyday on patients who might be experiencing discomfort.

And it turns out that vital signs in electronic medical records usually

have several spaces in which some new variable could be inserted.

And those variables in, in the vital signs are important,

because they can be graphed at some time during the life

of a patient follow-up, over a series of encounters.

And that would allow one to put in the results of some questionnaires

that evaluate the status of a patient with fibromyalgia,

at any point in time that they have a clinical visit.

And then, over a period or a series of clinical visits,

it would be possible to document change occurring overtime,

presumably as a result of the interventions that

the healthcare provider is providing to the patient.

That, I think, is going to be increasingly important with time because

we are told that in the future, physicians will be compensated for

the care of patients on the bases of outcomes.

So, did the patient improve?

Did the patient improve very much?

What proportion of improvement occurred in a patient?

And over the period in lets say a year many patents

if you look at one practice from one practice to another.

And that kind of improvement would be responsible for

determining compensation to the practice for that medical care.

If one has a ready graphic showing the improvement of

patients with fibromyalgia over a period of time that can be very handy in

documenting the improvement as a result of the level of care.

There have been a number of medical, medicine strategies that have been

tried over the years to treat people with fibromyalgia syndrome.

For example, there was a time when attempt was made to treat inflammation.

The amount of inflammation in fibromyalgia is relatively mild compared

to disorders such as rheumatoid arthritis or systemic lupus, but

there is some evidence of inflammation in the fibromyalgia patient.

So non-steroidal anti-inflammatory drugs and

Prednisone were tried, but they failed.

In contrast to the benefits that have been obtained by patients

with rheumatoid arthritis or systemic lupus using those

medications on a case, on a, on a repeated basis.

Another approach that was tried, was augmenting descending inhibition.

Last time in what causes fiber, fibromyalgia syndrome,

we talked about one of the potential causes,

that is interference with function of the descending

inhibition system by, because the chemicals of the,

the biogenic amines of descending inhibition are lower

than normal in people with fibromyalgia in their spinal fluid.

So, as a result, there were attempts to raise the levels of the biogenic amines,

serotonin, norepinephrine, and dopamine in research studies,

and those have generally met with some success.

In improving the symptoms of pain at least for people with fibromyalgia.

Another kind of experiment was attempted because substance P is

a amplifier of pain and

depression and a number of other symptoms in people with fibromyalgia.

So it was thought if we just block its reaction with

the NK1 receptor, its receptor,

then, perhaps we would prevent the effects of substance P.

But that was not successful, that failed.

And it's not really very clear why that failed, but

there may be other receptors that can accept the signal from substance P.

And then there was success with inhibition of nerve signal conduction,

nerve signal conduction in this case was inhibited.

What was, had gone awry, and was sending constant message of pain,

and the cer,

certain selective action, anticonvulsants

have been found to be successful in treating fibromyalgia.

And so, those would be of the alpha two

delta receptor ligand class and

examples of those would be like pregabalin or gabapentin.

And it has been found successful to correct insomnia, but

not just any approach to correcting insomnia is successful,

and we'll talk more about how to go about that.

In the next slide we see medications that have been used for fibromyalgia, and

we can see those medications which are directed at increasing serotonin and

norepinephrine in the spinal fluid of people with fibromyalgia where it is,

where the levels of those two biogenic amines are low.

And duloxetine and milnacipran have been

found to be effective and are approved by the Food and Drug Administration for

that purpose, their trade names are Cymbalta and Savella.

One of the anticonvulsant medications that has been used with success in

fibromyalgia and was approved for

treatment of fibromyalgia pain is pregabalin, or lyrica.

There have been medications that have met with success in

treating fibromyalgia but have never been taking to the FDA,

and have not received FDA approval for their use in fibromyalgia.

And they include a, an over the counter preparation called 5-hydroxytryptophan.

Somewhat similar to the, structure of, of serotonin

and useful in controlling the pain, and

perhaps influencing the sleep of people with fibromyalgia syndrome.

Then the tricyclics amitriptyline and cyclobenzaprine have been used.

We think of them as the older medications and less specific for

the, the biologic abnormalities of people with fibromyalgia because

they don't aren't as selective for a single receptor, or a dual receptor.

But they have been used with some success especially back when we didn't have

the newer medications that have subsequently been improved,

approved by the FDA.

Tramadol was useful in controlling pain of fibromyalgia but

does not have activity

of anti depressant nature as duloxetine,

and milnacipran did or do.

So it was never, it was effective in treating fibromyalgia,

it was more effective when combined with acetaminophen,

but has never been taken to the FDA for

evaluation of its ability to be approved for fibromyalgia.

And then we have a final category, not effective, and

the risks poorly justify use of these medications, and

they include opioids which many patients think are helpful to them,

but they don't really reduce the symptoms of fibromyalgia.

Non-steroidal anti-inflammatory drugs which seem to help

some people a little bit, but do carry a substantial risk

of gastric irritation, gastric erosions, gastric ulcers.

Acetaminophen which, in large quantities,

can be hazardous to liver function, and guaifenesin,

which has very little to argue in its favor.

The early medication category, these medications were found by

chance to offer some benefits in the treatment of fibromyalgia, but

were not FDA approved for fibromyalgia and really exhibit quite a few side effects.

The other problem with these medications that include primarily the tricyclides

was that they undergo tachyphylaxis, that means that after two months or

perhaps, three, they are no longer any more effective than a placebo.

And yet they carry the same potential for causing side effects such as

making the heart beat faster and causing severe dryness of the mouth.

So, also in this category were opioids which

seemed to offer risks rather than benefits in fibromyalgia patients.

Fibromyalgia patients' symptoms recede with opioids only to the extent,

we believe, that the patient is not so

conscious of their symptoms but really not helped.

Here we see a slide which shows one of the older medications,

that is an over the label, over the counter is available over

the counter in many countries, including the United States.

And this medication was studied by a group in Italy,

and we see a gradual slope down, suggesting improvement with the placebo.

But an even more rapid decline in the symptoms of

discomfort visual analog scale for pain, and,

they were highly, significantly different at the end of the first month of therapy.

That medication seems to begin to help very gradually,

and so I have been aware of patients who started

taking this medication and took it on a regular basis and

didn't even realize that they had improved.

The tricyclics are among the drugs that we have just discussed and.

You can see that in this slide we show a number of studies,

trials that were greater than eight weeks.

And we see the top study that, if you look at the far right-hand corner

did not show significant improvement in the people, in fibromyalgia symptoms,

compared to placebo, and that was Amitriptyline compared to placebo.

The next study comparing Amitriptyline or Cyclobenzaprine versus placebo,

did not show a significant benefit either.

However the third study did show significant benefit

when evaluating pain and the tender point score.

The fourth study, by Honan, Hannonen

did show benefit after a 12-week duration of treatment.

And the measures were visual analog scales for pain and sleep and

fatigue, and disability, so that seemed to be beneficial.

However the next study by didn't show benefit,

and the last two did seem to show some benefit.

So, this is kind of a mixed pattern, and

our belief is that back when we didn't have

anything else to treat fibromyalgia there was a chance that patients might benefit.

And we knew that they would get taciful access.

The drug would lose its benefit after a period of a few months and

we would stop the drug for a month or two, and then restart it, and

it would work again, for a period of time.

So, this is not optimal therapy, and we tend to set it aside for the present time.

The next group of studies have to do with analgesic drugs.

These are drugs which do not have much psychogenic potential,

do not alter mood to much of an extent, and

the first drug, Tramadol, particularly when compared with

when combined with acetaminophen, was beneficial in

research studies for up to three months duration.

Whereas two studies that we show using an opioid were not.

Neither were, was successful and helped significant,

providing significant improvement in pain in fibromyalgia.

That has been a puzzle to some physicians because opioids are helpful

in some other types of certainly acute pain and

maybe other types of chronic pain, but they are not successful or

useful in the treatment of fibromyalgia and should not be given to such patients.

When we look at the results of a tramadol study,

in this study what happened was that the patients were treated with tramadol until

they felt that they had improved as much as they were going to, and

then the medication was switched to blinded either tramadol or

placebo, and the investigators observed the rate at which the symptoms came back.

When the individuals were given placebo, the symptoms came back fairly quickly,

and continued at a fairly level rate, whereas when they were given,

allowed to continue blinded tramitol, the symptoms did not return at the same rate.

And so the Tramadol was shown and believed to be effective in helping these patients.

And then we come to a new group of medications,

not necessarily a class, but a group of medications, and

they are medications that were developed in response to biologic abnormalities, or

maybe one would use the term chemical pathogenesis in people with fibromyalgia.

And so the medications were created or found

that had the potential to, to help with these biologic abnormalities,

and they focused fairly directly on the abnormalities.

So they were focusing on specific treatment of an abnormality.

They, they were in general non-opioid and non-addicting.

They exhibited persistent benefit in therapeutic dosage.

That is most of them have been studied now for

an extended period of time, six months to a year, and they continued to

maintain the benefit that was seen at the point of around three months of therapy.

On the other hand, we can't say that they're curative.

The symptoms return when the medication is stopped.

And in some patients there are side effects associated with these

newer medications, that are so troublesome that they're intolerable.

The first of those medications to be developed and

applied to fibromyalgia, was Pregabalin.

Pregabalin is the generic name of this drug,

and Lyrica is the trade name of this medication.

Dr. Leslie Crawford led the group of investigators who studied

this drug in a randomized placebo controlled trial,

which was double-blinded and the results of the experiment were successful.

It was late, it, it was

discovered that this drug binds to a form

of calcium calcium channel.

And this voltage gated calcium channel,

then was prevented from leaking calcium

into the cell terminal at the synapse,

which has been allowing constant activation of the cell,

and leaking of neuro-molecules such as glutamate,

the neurotransmitter, and substance P.

So that constant flushing or

constant bombardment of the wide dynamic range neuron

was causing the individual to have constant and chronic pain.

And the theory is that with the pregabalin bound to

the alpha 2-delta receptor on this calcium channel,

there is a decrease in the amount of calcium, or

the rate at which calcium influx into the cell terminal occurs.

And as a result there is a decrease in the amount of neurotransmitter and

substance P being released into the synapse and as a result,

decreased pain experienced by the individual.

So, if we look at one of the research studies that

evaluated the benefit of this medication.

You can see first in the gray line the Placebo.

There is improvement among patients who are taking Placebo.

We see this in almost an,

in all of the clinical trials that are placebo-controlled.

And you can see why it is important and necessary that a Placebo be in,

are be included in the study, because if, if we thought this

was active medication you can see we do see improvement a decrease in.

The severity of pain over a period of weeks.

And so, we would think that the medication was effective, but

here we're using placebo, you can see a decrease associated with Placebo.

But even greater decrease in association with the drug at a dosage

of 300 milligrams, 450 milligrams and 600 milligrams.

When the FDA saw this data, they said, the 450 milligram and

the 600 milligram doses are not significantly different.

But, the 600 milligrams dosage does have associated with it,

an increase in the potential for adverse effects.

So, we think it would be wise to approve the 300, and 450 milligram dosage for

different individuals, for the treatment of Fibromyalgia pain.

But, not approve the 600 milligram dosage.

Another study was done

approximately the same time, with a different outcome measure.

In this case, instead of measuring pain,

the investigators are measuring improvement in sleep quality.

You can see that there is the same Placebo effect.

Seen in the red line up at the top,

a decrease in the severity of the pain of the sleep dysfunction.

But, an even greater change occurring with the 300 milligram,

450 milligram, and 600 milligram dosage.

It may be that the sleep benefits of this medication are in fact

better and usefully increased

in some patients with the 600 milligram dosage.

But, this is not included, the, the drug is not approved as a treatment for sleep.

Or improvement in sleep quality and so,

this information is currently waiting a useful expression.

So, then if we think about this drug Pregablin

as a medication that is capable of helping restorative sleep.

We could ask the question, is this drug a direct sedative?

That is, is it just making people sleepy, by a sedative effect?

Or, is it helping some of the, relieve some of the pain as an analgesic?

So that, then the person no longer hurts, and

is able to drop into restorative sleep.

And the answer was taken from two studies,

two research studies evaluating the effect of the drug on pain and sleep.

And the component of pain here was approximately 20%, so

there was a little bit of benefit in having the analgesic activity there,

but the majority of the sleep benefit was from a direct sedative effect of the drug.

Another study showed that the analgesic effect was

actually greater than or approximately equal to the sedative effect.

And so there may be some variation among individuals, among study groups.

But it appears that there is both an indirect Analgesic affect of the drug,

and a direct sedative effect responsible for the restorative sleep.

We would call this Mediational Analysis or

a analysis that is

looking at the direction of an effect, and

whether it is deviated through an indirect effect or only through the direct effect.

Now anytime we talk about a medication,

we should talk about adverse effects associated with the medication.

And in this table, we show the adverse events that are considered and

that were above a certain level, so they were included in the table.

But, then we can see the number of people who developed that out

of 500 and then see the percentage, and

which individuals developed that side effect with increasing

dosage of the medication.

And you can see that, one of the side effects that we need to think about

is Somnolence, day time somnolence.

Because this medication is, has sedative effects, and

as the medication is given, there is an increase in the number of

people who are developing this daytime somnolence with an increase in dosage.

So we, you would say that there is a dosage effect in this case.

The interesting thing about that is that if this medication,

instead of giving twice daily, morning and evening.

As indicated on the package insert, approved by the Food and

Drug Administration, if one gives this medication only at night,

then somnolence is a benefit.

Patients go to sleep more readily, and stay asleep more readily.

And so this sedative effect is a good thing,

if the medication is given at night.

Then instead of starting with the very low dosages like 75 milligrams,

it's possible to start the dosage at bedtime with 150 milligrams, and

most patients appreciate the better improvement in sleep that they experience.

We could look at dizziness as another side effect, that occur in as many as

43% of people taking the 450 milligram dose.

It's certainly appears as we move from Placebo up through 150,

300 and 450 milligrams to even 600 milligram dosage.

There is an increase in the frequency of that adverse event.

So we would say, there is a dosage effect of that, and

it's more frequent in higher, in inpatient's receiving higher dosage.

If that's the case, it may be related to the blood level in the patient.

And if we give the medication at bedtime,

the patient may be getting dizzy a little bit during the night, but

they're asleep because of the somnolent or sedative effect.

And so there are not aware of it, and

by the time they get up eight to nine hours later.

The level of the drug from that single dose has decreased enough, so

that it is not longer high enough to cause symptomatic dizziness.

And so most of our patients, given bed time dosage of

Verica do not experience the problem of dizziness.

Occasionally they do and when that occurs we encourage patients to be careful,

don't drive and, try to make sure that they have support so

that they don't fall and harm themselves and

that this side effect will go away in a period of a week or two and

that has essentially always happened in our experience.

Weight gain can happen in about 10% of patients, but I talked to patients and

about this, before I give the medication, I know you're going to be worried about

weight gain, and it says that it could happen in about 10% of patients,

but realize that this mediation has very few or any calories.

So if you gain weight, it's because maybe the medicine caused you to feel hungry,

and you ate too much at your meals or you ate between meals.

So we advise them to be very careful about the portions

of their meals keep the portion size the same, don't eat between meals and

we don't have much problem with weight gain, and in the rare case in which

the patient does gain some weight at least the doctor is not cause has not caused it.

The medicine has not so much caused it and

the patient realizes that they were not as

careful as they should have been with the amount of food that they ate.

So those are most of the side effects,

the more frequent side effects that we have to think about and

worry about occasionally peripheral edema, swelling of the legs, occurs it's,

uncertain whether it's responsive to a little bit of thiazide diuretic.

But it has been really not a big problem in our experience and

so we mention it to patients and patients read about it but

we don't we don't often have to be concerned.

The next drug to come on the research arena was

Duloxetine which we will recognize manny of you will recognize as Cymbalta.

That medication is a medication that increases

the levels or the effective, the availability of serotonin and

norepinephrine by blocking reuptake.

So, typically as we talked about in a previous session

regarding descending inhibition,.

The descending neuron axons come to the to a synapse and

they influence the cell that they're trying to inhibit

by releasing norepinephrine and serotonin into the synapse.

But one of the ways that the neuron reacts to that

biogenic amine that it secreted was to recover some of it.

Take it back up into the secreting axon

and that is referred to as uptake or reuptake.

So one of the ways that it has been possible to influence

the availability of those biogenic means at

the sites of inhibitory synapses is to

block the reuptake receptors with amitriptyline with a tricyclic drug,

with a selective serotonin reuptake inhibitor,

an SSRI, or in the case of duloxetine

with a serotonin norepinephrine reuptake inhibitor.

So it inhibits both serotonin and

norepinephrine in essentially the same way.

The same mechanism is seen with milnacipran and

they, its trade name is Isabella.

So we'll see now the effect of those medications,

Duloxetine Cymbalta had previously been approved as

an antidepressant medication so here we see results from a research study.

Treating major depression in people with depression,

not people with fibromyalgia, just depression.

And you can see that there is a placebo effect but the medicine has an effect

on depression and decreased the severity of depression or

measurement of depression on the Ham D scale

by a significant amount, beginning with maybe even the second week of therapy.

A significant difference from the placebo induced value and

that was with duloxetine at 60 milligrams every day.

So, now if we look at a study utilizing fibromyalgia patients, we see

decrease in the perception

of pain on the y-axis going from top to bottom.

And you can see that there is a placebo effect the red line here is placebo.

The green line is showing us the effect of 60 milligrams of duloxetine,

and the 10 line is showing the effect of 120 milligrams of duloxetine.

The decrease in the placebo is

not as great as with the active treatment in both of the dosage strengths.

And you can see that the green line persistently goes on out toward

the end of the study at approximately 28 weeks.

When the FDA reviewed this data, they said that the difference

between the 60-milligram dosage, and

the 120-milligram dosage in terms of benefit was vanishingly small but

that there were increased risk of adverse events.

And so 60 milligrams was approved for

the treatment of fibromyalgia with this medication.

Again, here we see, an analysis looking at mechanism of the drug.

And here we're asking the question,

if we give a person duloxatine, and pain relief is experience,

what do the research studies say has been the path of that improvement.

We saw somewhat similar type of question being

answered with Pregabalin on sleep improvement.

So you can see for the fibromyalgia patients.

A direct effect would be a direct pain or analgesic effect,

whereas an indirect effect would be an antidepressant effect.

Since it is widely perceived that

depressed patients experience discomfort and

that any discomfort they already have is increased because they are depressed.

You can see that one might wonder if pain relief might occur,

not just because it's a direct analgesic, but

because it has the ability to undercut depression and

anxiety, and that was responsible for

only 17% of the pain relief effect,

whereas fibromyalgia direct effect,

direct analgesic effect in the same study was 83%.

And with the with another research study shown

here in yellow highlight you can see that there,

this again is a greater effect of anal-, direct analgesic for

pain relief, but there is a a little more.

Approximately twice as much antidepressant effect influence on pain relief.

So, looking at the adverse effects profile for duloxetine,

we can see that the number one, top of the list

adverse event is nausea.

Below that dry mouth and constipation and so forth.

But let's just look at the nausea because it occurs in up to 31%

of people with 120 milligram dosage, but

the 60 milligram dosage that is the most common dosage for

treatment of fibromyalgia is also over

20% likely to cause nausea.

That's a high enough frequency that it is con,

of concern when a physician gives a patient this medication.

There are two things the physician can do when prescribing

Duloxetine to reduce the likelihood that this adverse effect will occur.

One of those is to give 30 milligrams of Duloxetine for

three to four days before increasing the dosage up to 60 milligrams.

That allows the person to become a little bit acclimated to the medicine in

their central nervous system, and decreases the likelihood that they will

experience nausea with this subsequent increase to 60 milligrams.

Another thing that can be done is for

the patient to take the medicine with breakfast.

When duloxetine is taken along with a food bolus,

the peak level of the peak blood level associated

with that dosage is less than it would be if the person took it just with water.

And as a result,

we believe that the nausea is related to this peaking of

the blood level, occurring shortly after taking the dose.

So when one takes food, with, takes the dosage with food,

there is not the sharp peak at the, very shortly after taking the medication,

but the curve spreads out over time, and the area under the curve remains the same.

So it is generally recommended that patients start taking this medication

with food in the morning, and then as they adapt to the medication,

they may be able to take it in the morning without having to eat food.

Other side effects associated with this medication can include

dizziness in about 10%, and a small number of

patients will lose appetite or have sweaty palms.

I've seen both of those experienced by patients and

weight loss can be persistent, although this medication is not

promoted as a weight loss medication.

The sweaty palm problem can be solved just by holding a napkin or

a Kleenex in ones' hand and then when reaching to shake someone's hand

the Kleenex or, or paper towel can be squeezed, and

the hand then does not seem to be cold and clammy and wet.

The drug milnacipran, has a very similar profile to that of Du, Duloxetine,

even though they are different structures, they both work on the same basis.

We think that Milnacipran has a slightly higher norepinephrine to serotonin ratio.

And you can see in this graph,

that Milnacipran at now sold as

has a placebo effect.

A decrease associated with the placebo group, and an even steeper and

clearly different level of effect associated with the active medication.

The adverse events profile is somewhat similar at 100, or 200 milligrams.

Here we show 200 milligrams a day, and in 100 milligrams, twice daily and

in this dosage, about 26% of patients experienced nausea.

And so the same kinds of suggestions have been promoted for

improving the tolerability of this medication.

Next I'd like to show a treatment model, based on the newer medications.

Drug selection would be based mostly on the most troublesome symptoms.

It's important to achieve a therapeutic dosage as soon as possible, so

that the patient can begin to make a valid choice between

the benefit associated with taking the medication and

any troublesome side effects they're experiencing.

And we believe that combination therapy from two

medications that work in completely different portions of

the pathogenesis of fibromyalgia may be a logical approach.

So my wife and I went on a vacation trip to

the Arenal volcano in Costa Rica.

And while we were there, it struck me that this mountain,

with its peak of fire coming out the top, looked very much like a triangle.

And thinking much about fibromyalgia at the time.

I thought maybe we could represent the fire breathing

dragon here of this triangle as the pain of fibromyalgia

since it was one of the most troublesome symptoms.

And we could represent depression.

At one of the lower base of the triangle.

And at the other base we could represent insomnia, or sleep dysfunction.

Now, I've made the word depression smaller in size on purpose.

The reason for this is that pain

exists in people with fibromyalgia at a rate of about 100%.

Because it is necessary to both of the two

criteria, diagnostic criteria that I used the 1990,

and the 2010 American College of Rheumatology criteria.

Depression occurs in about 35% of patients with fibromyalgia,

and sleep dysfunction between 70%, 80%, and 95% of patients.

So both pain and insomnia are highly common among this population,

and depression is only about a third of those patients.

In using this diagram to predict treatment,

I have proposed that the physician is seeing the patient from the top.

And so the physician sees pain first and

knows that it is going to be necessary to treat pain.

But then, looking out to the right hand side of this patient represented

by a triangle one would see depression and might say depression

can be very miserable and we would certainly want to treat that as well.

Or could look down and see insomnia and say we must treat that because

that is very serious problem and is really troubling this patient.

So lets assume that we see depression here, and

we say we want to treat depression but we want to treat the pain also.

We could use Tremadol, which is has effectiveness in fibromyalgia for

treatment of pain, but is not an antidepressant and doesn't have that

activity, so an SSRI could be used for treatment of the depression.

Then a sedative of some sort wouldn't be needed for the insomnia.

Better, I think, to use, perhaps, duloxetine, Cymbalta,

or milnacipran, but duloxetine has an indication for

depression in the United States, which milnacipran doesn't.

Duloxetine can treat the pain and the depression.

Both ends of this side bar, and so

it seems like reasonable approach to begin treatment of a depressed

patient with [INAUDIBLE] depressed fibromyalgia patient with duloxetine.

Then once that depression is managed or if the patient is already on an SSRI for

treatment of depression we may not wish to disturb that and

we might say let's treat the sleep with a medication that is known

to help sleep in fibromyalgia, and also help pain.

And so, Pregabalin in approved for the indication of treating pain of

fibromyalgia, and we might use that to treat insomnia here.

Or in a patient who we have started on duloxatine because of depression and

maintenance of control of pain, we might then, once the patient is stabilized on

their duloxetine therapy in the morning, we might add pregabalin at bedtime.

And my typical approach is to

start duloxetine as 30 milligrams for three to four days,

then increase it to 60 milligrams wait a week, or two weeks, or three weeks and

then start Pregabalin for the pain and in, remaining pain and insomnia.

And the dosage that I usually start with is 150 milligrams but realize.

That I'm giving this dosage at bedtime, rather than the morning.

Patients are very tired from having slept very poorly for a long period of time.

And so if we give a dose in the morning,

they are likely to experience sedation from that medication.

That might frighten them and make them not want to take the medication.

So giving it to them at night has many benefits.

It provides them sedation for sleep during the night.

It avoids the problem

pretty much avoids the problem of having a side-effect of dizziness.

And in addition to those things, patients will be sleeping more deeply,

getting more restorative sleep, and awakening feeling more,

rested and refreshed, and not so fatigued during the day.

So, in summary, fibromyalgia management is focussed on the chemical causes.

The drugs were developed

to or were proposed as medications that could

work on specific components of the fibromyalgia abnormalities.

Such as afferent signaling of pain it,

using pregabalin, and descend,

failure of descending inhibition using the duloxatine.

Therapeutic agents now exist for most of the manifestations of fibromyalgia.

Evidence for benefit is good for the newer medications.

And combinations of certain medications in,

under certain circumstances may increase the benefit but

also we must be aware that they may increase also the risk.

And so, we see our happy dog here

happy because we're making progress with the treatment of fibromyalgia.

Thank you for your attention.

So the second one is going to be shorter.

Explorer notre catalogue

Rejoignez-nous gratuitement et obtenez des recommendations, des mises à jour et des offres personnalisées.

Coursera propose un accès universel à la meilleure formation au monde, en partenariat avec des universités et des organisations du plus haut niveau, pour proposer des cours en ligne.

© 2019 Coursera Inc. Tous droits réservés.

Télécharger dans l'App Store

Disponible sur Google Play

Coursera
À propos
Direction
Carrières
Catalogue
Certificats
Certificats MasterTrack™
Diplômes
For Enterprise
For Government

Communauté
Learners
Partners
Developers
Beta Testers
Translators

Se connecter
Blog
Facebook
LinkedIn
Twitter
Instagram
YouTube
Blog Tech

Plus
Conditions
Confidentialité
Aide
Accessibilité
Presse
Contact
Répertoire
Filiales